• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    NanoViricides, Inc. Common Stock (NY: NNVC )

    1.230 -0.060 (-4.65%)
    Streaming Delayed Price Updated: 3:20 PM EDT, Mar 12, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 109,790
    Open 1.300
    Bid (Size) 1.220 (7)
    Ask (Size) 1.230 (3)
    Prev. Close 1.290
    Today's Range 1.220 - 1.310
    52wk Range 1.030 - 3.590
    Shares Outstanding 15,641,611
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Antiviral Pipeline, Positions Stock as Market Hedge
    Via Investor Brand Network
    Topics Intellectual Property World Trade
    Exposures COVID-19 Intellectual Property Tariff
    NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
    Via ACCESS Newswire

    Performance

    YTD
    -13.38%
    -13.38%
    1 Month
    -6.11%
    -6.11%
    3 Month
    -16.89%
    -16.89%
    6 Month
    -23.13%
    -23.13%
    1 Year
    +9.82%
    +9.82%

    More News

    Read More
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Measles Treatment Amid Outbreak
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property Product Safety
    Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
    Via ACCESS Newswire
    NanoViricides, Inc. Has Filed its Quarterly Report
    Via ACCESS Newswire
    Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
    Via ACCESSWIRE
    BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financials, Advances NV-387 Antiviral Trials
    Via Investor Brand Network
    Topics Intellectual Property Regulatory Compliance
    Exposures COVID-19 Intellectual Property Legal
    BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Claims NV-387 Ready to Combat Bird Flu
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Showcases NV-387’s Broad-Spectrum Antiviral Potential at MicroCap Conference
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Partners with CRO to Advance NV-387 Antiviral Drug to Phase II Trials
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    NanoViricides Engages CRO for Phase II Clinical Trial
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Broad-Spectrum Antiviral Innovations at Biotech Showcase 2025
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
    Via ACCESSWIRE
    BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387 as a Broad-Spectrum Antiviral Solution to Emerging Threats
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Touts NV-387 as Key Defense Against Potential Bird Flu Pandemic
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
    Via ACCESSWIRE
    DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
    Via ACCESSWIRE
    BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financial Progress and Advances Towards Key Phase II Clinical Trials
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
    Via ACCESSWIRE
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Advancements at Spartan Capital Investors Conference
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
    Via ACCESSWIRE
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform and Drug Delivery Advances at PODD Conference
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    NanoViricides President Dr. Diwan to Present at the PODD Conference
    Via ACCESSWIRE
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.